DSGN
Price
$9.77
Change
+$0.83 (+9.28%)
Updated
Dec 3 closing price
Capitalization
556.54M
103 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$32.20
Change
+$3.80 (+13.38%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
2.22B
84 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DSGN vs SYRE

Header iconDSGN vs SYRE Comparison
Open Charts DSGN vs SYREBanner chart's image
Design Therapeutics
Price$9.77
Change+$0.83 (+9.28%)
Volume$957.03K
Capitalization556.54M
Spyre Therapeutics
Price$32.20
Change+$3.80 (+13.38%)
Volume$57.92K
Capitalization2.22B
DSGN vs SYRE Comparison Chart in %
DSGN
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DSGN vs. SYRE commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DSGN is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (DSGN: $8.96 vs. SYRE: $28.40)
Brand notoriety: DSGN and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DSGN: 91% vs. SYRE: 23%
Market capitalization -- DSGN: $509.83M vs. SYRE: $2.22B
DSGN [@Biotechnology] is valued at $509.83M. SYRE’s [@Biotechnology] market capitalization is $2.22B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DSGN’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • DSGN’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both DSGN and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DSGN’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • DSGN’s TA Score: 5 bullish, 4 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DSGN is a better buy in the short-term than SYRE.

Price Growth

DSGN (@Biotechnology) experienced а -4.78% price change this week, while SYRE (@Biotechnology) price change was -2.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

DSGN is expected to report earnings on Mar 17, 2026.

SYRE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($2.22B) has a higher market cap than DSGN($557M). DSGN YTD gains are higher at: 45.219 vs. SYRE (21.993). DSGN has higher annual earnings (EBITDA): -74.31M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. DSGN (216M). SYRE has less debt than DSGN: SYRE (0) vs DSGN (1.95M). DSGN (0) and SYRE (0) have equivalent revenues.
DSGNSYREDSGN / SYRE
Capitalization557M2.22B25%
EBITDA-74.31M-222.15M33%
Gain YTD45.21921.993206%
P/E RatioN/A1.72-
Revenue00-
Total Cash216M527M41%
Total Debt1.95M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
74
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DSGNSYRE
RSI
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 6 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 6 days ago
88%
Momentum
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 6 days ago
87%
MACD
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 6 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 6 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 6 days ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
88%
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 21 days ago
84%
Bearish Trend 28 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 6 days ago
90%
Aroon
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 6 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
DSGN
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PXIIX22.07N/A
N/A
Virtus KAR Equity Income I
GLPCX30.13N/A
N/A
Goldman Sachs MLP Energy Infras C
JCVVX25.41N/A
N/A
JHancock Classic Value R5
ATHGX29.52N/A
N/A
American Century Heritage R5
VIKSX10.43N/A
N/A
Virtus KAR Small-Mid Cap Growth I

DSGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DSGN has been loosely correlated with IDYA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DSGN jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DSGN
1D Price
Change %
DSGN100%
+0.11%
IDYA - DSGN
52%
Loosely correlated
-1.75%
CRNX - DSGN
48%
Loosely correlated
-0.53%
WVE - DSGN
48%
Loosely correlated
-5.67%
VRDN - DSGN
48%
Loosely correlated
-3.26%
SYRE - DSGN
48%
Loosely correlated
-0.91%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with APGE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-0.91%
APGE - SYRE
58%
Loosely correlated
+0.20%
CGON - SYRE
58%
Loosely correlated
-4.35%
RGNX - SYRE
57%
Loosely correlated
-3.10%
IDYA - SYRE
57%
Loosely correlated
-1.75%
ORKA - SYRE
56%
Loosely correlated
+0.56%
More